The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report.
The prevention of recurrences of bladder cancer was attemped in 48 patients by means of the combined intravesical instillation of thio-tepa and urokinase and in 28 patients through the instillation of thio-tepa alone. The recurrence rates of both therapies for the postoperative 18 months were 7.9 and 32.6 per cent, respectively, indicating a significant drop in the recurrence rate in the group subjected to the combined therapy. No significant difference was found between the 2 instillation groups in terms of the blood transmission of 32-P thio-tepa. Serious leukopenia was found in 2 of the 48 patients receiving the combined instillation therapy but we concluded that this was not attributable to the use of urokinase.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000517:prevention & control*; D003556:Cystitis / Q000139:chemically induced; D004359:Drug Therapy, Combination; D010450:Endopeptidases / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D010761:Phosphorus Radioisotopes; D013852:Thiotepa / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001745:Urinary Bladder Diseases / Q000139:chemically induced; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control*; D014568:Urokinase-Type Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use*
D010761:Phosphorus Radioisotopes; D013852:Thiotepa; D010450:Endopeptidases; D014568:Urokinase-Type Plasminogen Activator